Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 13/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.64 |
| ▸ | DRD4 | P21917 | 13/20 | 0.48 |
| ▸ | DRD3 | P35462 | 13/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 11/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 11/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 11/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6577992 | 0.79 | DRD2 (0.70) | DRD2CHRM1KCNH2DRD4DRD3 | |
| SCHEMBL6580350 | 0.78 | CHRM1 (1.00) | DRD2CHRM1KCNH2DRD4DRD3 | |
| SCHEMBL6580566 | 0.77 | DRD2 (0.68) | DRD2CHRM1KCNH2DRD4DRD3 | |
| SCHEMBL5389927 | 0.76 | DRD2 (0.75) | DRD2DRD4DRD3 | |
| SCHEMBL6580501 | 0.74 | DRD2 (0.68) | DRD2CHRM1KCNH2DRD4DRD3 | |
| SCHEMBL5392500 | 0.74 | DRD2 (0.75) | DRD2DRD4DRD3 | |
| SCHEMBL7048455 | 0.74 | — | — | |
| SCHEMBL5387582 | 0.74 | DRD2 (0.75) | DRD2DRD4DRD3 | |
| SCHEMBL6580634 | 0.73 | DRD2 (0.62) | DRD2CHRM1KCNH2DRD4DRD3 | |
| SCHEMBL6578149 | 0.72 | GRIN1 (0.66) | DRD2CHRM1KCNH2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299380-B1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2004-06-09 | — | — | EP | disclosed |
| US-20030232822-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DE) | 2003-12-18 | — | — | US | disclosed |
| EP-1299380-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002000645-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232822-A1 | Indole derivatives useful for the treatment of CNS disorders | CHRM1, TPH1, CHRNA6 | DRD2 162/4885CHRM1 1/4885KCNH2 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.